{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:02:56Z","timestamp":1793059376624,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001518","name":"Maurice and Phyllis Paykel Trust","doi-asserted-by":"publisher","award":["193119"],"award-info":[{"award-number":["193119"]}],"id":[{"id":"10.13039\/501100001518","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Tranexamic acid (TXA) has been shown to be effective at reducing peri-operative blood loss and haemarthrosis in arthroplasty and arthroscopic soft tissue reconstructions. Intra-articular application, as an injection or peri-articular wash, is becoming increasingly common. Recent studies have shown TXA has the potential to be cytotoxic to cartilage, but its effects on human tendon and bone remain poorly understood. The aim of this study was to investigate whether TXA has any detrimental effects on tendon-derived cells and osteoblast-like cells and determine whether there is a safe dosage for clinical application.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Primary tendon-derived cells and osteoblast-like cells were harvested from hamstring tendons and trabecular bone explants, respectively, and analysed in vitro with a range of TXA concentrations (0 to 100\u00a0mg\/ml) at time points: 3 and 24\u00a0h. The in vitro toxic effect of TXA was investigated using viability assays (alamarBlue), functional assays (collagen deposition), fluorescent microscopy and live\/apoptosis\/necrosis staining for cell death mechanisms in 2D monolayer and 3D collagen gel cell culture.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a significant (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) decrease in tendon-derived cell and osteoblast-like cell numbers following treatment with TXA\u2009\u2265\u200950\u00a0mg\/ml after 3\u00a0h and\u2009\u2265\u200920\u00a0mg\/ml after 24\u00a0h.  In tendon-derived cells, increasing concentrations\u2009&gt;\u200935\u00a0mg\/ml resulted in significantly (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) reduced collagen deposition. Fluorescence imaging confirmed atypical cellular morphologies with increasing TXA concentrations and reduced cell numbers. The mechanism of cell death was demonstrated to be occurring through apoptosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Topical TXA treatment demonstrated dose- and time-dependent cytotoxicity to tendon-derived cells and osteoblast-like cells with concentrations 20\u00a0mg\/ml and above in isolated 2D and 3D in vitro culture. On the basis of these findings, concentrations of less than 20\u00a0mg\/ml are expected to be safe. Orthopaedic surgeons should show caution when considering topical TXA treatments, particularly in soft tissue and un-cemented arthroplasty procedures.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13018-022-03167-5","type":"journal-article","created":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T07:03:57Z","timestamp":1652598237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cytotoxicity of tranexamic acid to tendon and bone in vitro: Is there a safe dosage?"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0197-307X","authenticated-orcid":false,"given":"Scott M.","family":"Bolam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arama","family":"O\u2019Regan-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajit","family":"Konar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Callon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Paul","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Musson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob T.","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"3167_CR1","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.arth.2015.12.033","volume":"31","author":"AK Aggarwal","year":"2016","unstructured":"Aggarwal AK, Singh N, Sudesh P. Topical vs intravenous tranexamic acid in reducing blood loss after bilateral total knee arthroplasty: a prospective study. J Arthroplasty. 2016;31:1442\u20138.","journal-title":"J Arthroplasty"},{"key":"3167_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3109\/17453677608988725","volume":"47","author":"A Ahlberg","year":"1976","unstructured":"Ahlberg A, Eriksson O, Kjellman H. Diffusion of tranexamic acid to the joint. Acta Orthop Scand. 1976;47:486\u20138.","journal-title":"Acta Orthop Scand"},{"key":"3167_CR3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00167-017-4746-9","volume":"27","author":"LF Ambra","year":"2019","unstructured":"Ambra LF, de Girolamo L, Niu W, Phan A, Spector M, Gomoll AH. No effect of topical application of tranexamic acid on articular cartilage. Knee Surg Sport Traumatol Arthrosc. 2019;27:931\u20135.","journal-title":"Knee Surg Sport Traumatol Arthrosc"},{"key":"3167_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1749-799X-8-5","volume":"8","author":"V Bahl","year":"2013","unstructured":"Bahl V, Goyal A, Jain V, Joshi D, Chaudhary D. Effect of haemarthrosis on the rehabilitation of anterior cruciate ligament reconstruction- single bundle versus double bundle. J Orthop Surg Res. 2013;8:5.","journal-title":"J Orthop Surg Res"},{"key":"3167_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22010449","volume":"22","author":"A Baranowsky","year":"2021","unstructured":"Baranowsky A, Appelt J, Tseneva K, Jiang S, Jahn D, Tsitsilonis S, Frosch KH, Keller J. Tranexamic acid promotes murine bone marrow-derived osteoblast proliferation and inhibits osteoclast formation in vitro. Int J Mol Sci. 2021;22:1\u201313.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3167_CR6","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00167-020-06219-7","volume":"29","author":"SM Bolam","year":"2021","unstructured":"Bolam SM, O\u2019Regan-Brown A, Paul Monk A, Musson DS, Cornish J, Munro JT. Toxicity of tranexamic acid (TXA) to intra-articular tissue in orthopaedic surgery: a scoping review. Knee Surg Sports Traumatol Arthrosc. 2021;29(6):1862\u201371.","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"issue":"2","key":"3167_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1302\/2046-3758.82.BJR-2018-0099.R1","volume":"8","author":"P Busse","year":"2019","unstructured":"Busse P, Vater C, Stiehler M, Nowotny J, Kasten P, Bretschneider H, Goodman SB, Gelinsky M, Zwingenberger S. Cytotoxicity of drugs injected into joints in orthopaedics. Bone Joint Res. 2019;8(2):41\u20138.","journal-title":"Bone Joint Res"},{"key":"3167_CR8","doi-asserted-by":"publisher","first-page":"e4656","DOI":"10.1097\/MD.0000000000004656","volume":"95","author":"Y Chen","year":"2016","unstructured":"Chen Y, Chen Z, Cui S, Li Z, Yuan Z. Topical versus systemic tranexamic acid after total knee and hip arthroplasty: a meta-analysis of randomized controlled trials. Medicine. 2016;95:e4656\u2013e4656.","journal-title":"Medicine"},{"key":"3167_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/annrheumdis-2013-204657","volume":"73","author":"A Chhana","year":"2014","unstructured":"Chhana A, Callon KE, Dray M, Pool B, Naot D, Gamble GD, Coleman B, McCarthy G, McQueen FM, Cornish J, Dalbeth N. Interactions between tenocytes and monosodium urate monohydrate crystals: Implications for tendon involvement in gout. Ann Rheum Dis. 2014;73:1737\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3167_CR10","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.arthro.2019.02.018","volume":"35","author":"ER Chiang","year":"2019","unstructured":"Chiang ER, Chen KH, Wang ST, Ma HL, Chang MC, Liu CL, Chen TH. Intra-articular injection of tranexamic acid reduced postoperative hemarthrosis in arthroscopic anterior cruciate ligament reconstruction: a prospective randomized study. Arthrosc J Arthrosc Related Surg. 2019;35(7):2127\u201332.","journal-title":"Arthrosc J Arthrosc Related Surg"},{"key":"3167_CR11","doi-asserted-by":"publisher","first-page":"E1132","DOI":"10.1097\/BRS.0000000000000488","volume":"39","author":"JM Cuellar","year":"2014","unstructured":"Cuellar JM, Yoo A, Tovar N, Coelho PG, Jimbo R, Vandeweghe S, Kirsch T, Quirno M, Errico TJ. The effects of Amicar and TXA on lumbar spine fusion in an animal model. Spine. 2014;39:E1132-7.","journal-title":"Spine"},{"key":"3167_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.22203\/eCM.v021a21","volume":"21","author":"J Demol","year":"2011","unstructured":"Demol J, Eyckmans J, Roberts SJ, Luyten FP, Van Oosterwyck H. Does tranexamic acid stabilised fibrin support the osteogenic differentiation of human periosteum derived cells? Eur Cell Mater. 2011;21:272\u201385.","journal-title":"Eur Cell Mater"},{"key":"3167_CR13","first-page":"439","volume":"45","author":"JF DiBlasi","year":"2016","unstructured":"DiBlasi JF, Smith RP, Garavaglia J, Quedado J, Frye BM, Dietz MJ. Comparing cost, efficacy, and safety of intravenous and topical tranexamic acid in total hip and knee arthroplasty. Am J Orthop. 2016;45:439\u201343.","journal-title":"Am J Orthop"},{"key":"3167_CR14","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1182\/blood.V122.21.3629.3629","volume":"122","author":"J Dyba","year":"2013","unstructured":"Dyba J, Chan F, Lau K, Chan A, Chan H. Tranexamic acid is a weak provoking factor for thromboembolic events: a systematic review of the literature. Blood. 2013;122:3629.","journal-title":"Blood"},{"key":"3167_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1756-0500-6-184","volume":"6","author":"R Gandhi","year":"2013","unstructured":"Gandhi R, Evans HMK, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013;6:184.","journal-title":"BMC Res Notes"},{"issue":"1","key":"3167_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-019-0373-x","volume":"24","author":"R Goderecci","year":"2019","unstructured":"Goderecci R, Giusti I, Necozione S, Cinque B, D\u2019Ascenzo S, Dolo V, Calvisi V. Short exposure to tranexamic acid does not affect, in vitro, the viability of human chondrocytes. Eur J Med Res. 2019;24(1):1\u201310.","journal-title":"Eur J Med Res"},{"key":"3167_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.arth.2016.07.004","volume":"32","author":"N Goyal","year":"2017","unstructured":"Goyal N, Chen DB, Harris IA, Rowden NJ, Kirsh G, MacDessi SJ. Intravenous vs Intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind trial. J Arthroplasty. 2017;32:28\u201332.","journal-title":"J Arthroplasty"},{"key":"3167_CR18","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1177\/0363546515599629","volume":"43","author":"F Karaaslan","year":"2015","unstructured":"Karaaslan F, Karao\u0287lu S, Yurdakul E. Reducing intra-articular hemarthrosis after arthroscopic anterior cruciate ligament reconstruction by the administration of intravenous tranexamic acid. Am J Sports Med. 2015;43:2720\u20136.","journal-title":"Am J Sports Med"},{"key":"3167_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/00003086-200204000-00049","volume":"397","author":"PM Lamberti","year":"2002","unstructured":"Lamberti PM, Wezeman FH. Biologic behavior of an in vitro hydrated collagen gel\u2013human tenocyte tendon model. Clin Orthop Relat Res. 2002;397:414\u201323.","journal-title":"Clin Orthop Relat Res"},{"key":"3167_CR20","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1007\/s11999-012-2310-y","volume":"470","author":"RN Maniar","year":"2012","unstructured":"Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012;470:2605\u201312.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"3167_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-015-0856-z","volume":"17","author":"Z Mao","year":"2016","unstructured":"Mao Z, Yue B, Wang Y, Yan M, Dai K. A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty. BMC Musculoskel Disord. 2016;17(1):1\u20138.","journal-title":"BMC Musculoskel Disord"},{"key":"3167_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2014.55","author":"BG Matthews","year":"2014","unstructured":"Matthews BG, Naot D, Callon KE, Musson DS, Locklin R, Hulley PA, Grey A, Cornish J. Enhanced osteoblastogenesis in three-dimensional collagen gels. Bonekey Rep Portico. 2014. https:\/\/doi.org\/10.1038\/bonekey.2014.55.","journal-title":"Bonekey Rep Portico"},{"key":"3167_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1302\/2046-3758.81.BJR-2018-0181.R1","volume":"8","author":"M McLean","year":"2019","unstructured":"McLean M, McCall K, Smith IDM, Blyth M, Kitson SM, Crowe LAN, Leach WJ, Rooney BP, Spencer SJ, Mullen M, Campton JL, McInnes IB, Akbar M, Millar NL. Tranexamic acid toxicity in human periarticular tissues. Bone Joint Res. 2019;8:11\u20138.","journal-title":"Bone Joint Res"},{"key":"3167_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1302\/2046-3758.68.BJR-2017-0005.R1","volume":"6","author":"RJM Morrison","year":"2017","unstructured":"Morrison RJM, Tsang B, Fishley W, Harper I, Joseph JC, Reed MR. Dose optimisation of intravenous tranexamic acid for elective hip and knee arthroplasty: the effectiveness of a single pre-operative dose. Bone Joint Res. 2017;6:499\u2013505.","journal-title":"Bone Joint Res"},{"key":"3167_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1213\/ANE.0b013e3181c92b23","volume":"110","author":"JM Murkin","year":"2010","unstructured":"Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010;110:350\u20133.","journal-title":"Anesth Analg"},{"key":"3167_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-019-1089-x","author":"DS Musson","year":"2019","unstructured":"Musson DS, Gao R, Watson M, Lin JM, Park YE, Tuari D, Callon KE, Zhu M, Dalbeth N, Naot D, Munro JT, Cornish J. Bovine bone particulates containing bone anabolic factors as a potential xenogenic bone graft substitute. J Orthop Surg Res. 2019. https:\/\/doi.org\/10.1186\/s13018-019-1089-x.","journal-title":"J Orthop Surg Res"},{"key":"3167_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1089\/ten.tea.2014.0128","volume":"21","author":"DS Musson","year":"2015","unstructured":"Musson DS, Naot D, Chhana A, Matthews BG, McIntosh JD, Lin STC, Choi AJ, Callon KE, Dunbar PR, Lesage S, Coleman B, Cornish J. In vitro evaluation of a novel non-mulberry silk scaffold for use in tendon regeneration. Tissue Eng Part A. 2015;21:1539\u201351.","journal-title":"Tissue Eng Part A"},{"key":"3167_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/jcp.33.Suppl_14.41","volume":"14","author":"IM Nilsson","year":"1980","unstructured":"Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol). 1980;14:41\u20137.","journal-title":"J Clin Pathol Suppl (R Coll Pathol)"},{"issue":"5","key":"3167_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.knee.2013.05.014","volume":"20","author":"M Panteli","year":"2013","unstructured":"Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. The Knee. 2013;20(5):300\u20139.","journal-title":"The Knee"},{"key":"3167_CR30","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1302\/0301-620X.100B3.BJJ-2017-1135.R1","volume":"100B","author":"JD Parker","year":"2018","unstructured":"Parker JD, Lim KS, Kieser DC, Woodfield TBF, Hooper GJ. Is tranexamic acid toxic to articular cartilage when administered topically? J Bone Jt Surgery Br. 2018;100B:404\u201312.","journal-title":"J Bone Jt Surgery Br"},{"issue":"3","key":"3167_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1302\/0301-620X.100B3.BJJ-2017-1135.R1","volume":"100","author":"JD Parker","year":"2018","unstructured":"Parker JD, Lim KS, Kieser DC, Woodfield TBF, Hooper GJ. Is tranexamic acid toxic to articular cartilage when administered topically? What is the safe dose? Bone Joint J. 2018;100(3):404\u201312.","journal-title":"Bone Joint J"},{"key":"3167_CR32","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1136\/bmj.g4829","volume":"349","author":"J Poeran","year":"2014","unstructured":"Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014;349:4829.","journal-title":"BMJ"},{"key":"3167_CR33","doi-asserted-by":"publisher","first-page":"164206","DOI":"10.1155\/2015\/164206","volume":"2015","author":"P Sa-Ngasoongsong","year":"2015","unstructured":"Sa-Ngasoongsong P, Chanplakorn P, Wongsak S, Uthadorn K, Panpikoon T, Jittorntam P, Aryurachai K, Angchaisukisiri P, Kawinwonggowit V. An in vivo study of low-dose intra-articular tranexamic acid application with prolonged clamping drain method in total knee replacement: clinical efficacy and safety. Biomed Res Int. 2015;2015:164206.","journal-title":"Biomed Res Int"},{"key":"3167_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-2474-14-340","volume":"14","author":"P Sa-Ngasoongsong","year":"2013","unstructured":"Sa-Ngasoongsong P, Wongsak S, Chanplakorn P, Woratanarat P, Wechmongkolgorn S, Wibulpolprasert B, Mulpruek P, Kawinwonggowit V. Efficacy of low-dose intra-articular tranexamic acid in total knee replacement; a prospective triple-blinded randomized controlled trial. BMC Musculoskelet Disord. 2013;14:340.","journal-title":"BMC Musculoskelet Disord"},{"key":"3167_CR35","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00167-012-2079-2","volume":"21","author":"J-GG Seo","year":"2013","unstructured":"Seo J-GG, Moon Y-WW, Park S-HH, Kim S-MM, Ko K-RR. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sport Traumatol Arthrosc. 2013;21:1869\u201374.","journal-title":"Knee Surg Sport Traumatol Arthrosc"},{"issue":"11","key":"3167_CR36","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1016\/j.arthro.2019.09.007","volume":"35","author":"MG Siegel","year":"2019","unstructured":"Siegel MG. The dangers and concerns of intra-articular tranexamic acid. Arthroscopy. 2019;35(11):2973\u20134.","journal-title":"Arthroscopy"},{"key":"3167_CR37","first-page":"497","volume":"44","author":"JR Tuttle","year":"2015","unstructured":"Tuttle JR, Feltman PR, Ritterman SA, Ehrlich MG. Effects of tranexamic acid cytotoxicity on in vitro chondrocytes. Am J Orthop. 2015;44:497\u2013502.","journal-title":"Am J Orthop"},{"key":"3167_CR38","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.arth.2016.04.036","volume":"31","author":"TK Tzatzairis","year":"2016","unstructured":"Tzatzairis TK, Drosos GI, Kotsios SE, Ververidis AN, Vogiatzaki TD, Kazakos KI. Intravenous vs topical tranexamic acid in total knee arthroplasty without tourniquet application: a randomized controlled study. J Arthroplasty. 2016;31:2465\u201370.","journal-title":"J Arthroplasty"},{"key":"3167_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2165\/00003495-198529030-00003","volume":"29","author":"M Verstraete","year":"1985","unstructured":"Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29:236\u201361.","journal-title":"Drugs"},{"key":"3167_CR40","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.3390\/jcm9123880","volume":"9","author":"M Wagenbrenner","year":"2020","unstructured":"Wagenbrenner M, Heinz T, Horas K, Jakuscheit A, Arnholdt J, Mayer-Wagner S, Rudert M, Holzapfel BM, Wei\u00dfenberger M. Impact of tranexamic acid on chondrocytes and osteogenically differentiated human mesenchymal stromal cells (hMSCs) in vitro. J Clin Med MDPI AG. 2020;9:3880.","journal-title":"J Clin Med MDPI AG"},{"key":"3167_CR41","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1097\/MD.0000000000006916","volume":"96","author":"H Zhang","year":"2017","unstructured":"Zhang H, He G, Zhang CCC, Xu B, Wang X, Zhang CCC. Is combined topical and intravenous tranexamic acid superior to intravenous tranexamic acid alone for controlling blood loss after total hip arthroplasty?: a meta-analysis. Medicine. 2017;96:6916\u20136916.","journal-title":"Medicine"},{"key":"3167_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00132-016-3252-y","volume":"45","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zhang L, Ma X, Jia Y, Wang H, Zhu Y, Liu Y. What is the optimal approach for tranexamic acid application in patients with unilateral total hip arthroplasty? Orthop\u00e4de. 2016;45:616\u201321.","journal-title":"Orthop\u00e4de"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-022-03167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-022-03167-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-022-03167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T07:07:43Z","timestamp":1652598463000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-022-03167-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3167"],"URL":"https:\/\/doi.org\/10.1186\/s13018-022-03167-5","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human tissue donors provided written informed consent collection of samples. Human sample collection was approved by the New Zealand Ministry of Health Northern Regional Ethics Committee (NTX\/05\/06\/058\/AM14).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}